MarketPeel
Insider Trading Intelligence
Pricing
…
BS

Barry J. Simon

IBRX
DIRECTOR · IMMUNITYBIO, INC. · CIK 0001647994
FILING MIX · LIFETIME39%/61%
BUYS
12
SELLS
19
TOTAL VALUE
$6.62M
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
2,812,788
AVG SELL PX
$10.36
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 15 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Barry J. Simon, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+37.50%+2.88%+0.76%+2.13%+7.42%—
14d8+87.50%-5.28%+0.31%-5.60%-3.35%—
30d8+62.50%-1.49%-0.99%-0.51%-10.76%—
60d8+75.00%-12.02%+2.14%-14.16%-30.74%—
90d8+75.00%-15.43%+5.98%-16.18%-37.88%—
180d8(5 pending)+100.00%-58.83%+12.89%-71.72%-71.63%—
1y8(5 pending)+100.00%-76.57%-4.46%-72.11%-71.77%—
2y8(5 pending)+100.00%-83.67%+2.40%-86.07%-86.44%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IBRX · 2,802,788 shares · as of Jun 24, 2026
0812,2561,624,5122,436,7683,249,02420222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 19 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
25,000$7.88$196.9K2,802,788Jun 24, 2026Jun 26, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
23,033$7.18$165.3K2,827,788Jun 4, 2026Jun 5, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
75,000$12.01$900.8K2,850,821Feb 24, 2026Feb 26, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
165,000$10.25$1.69M2,925,821Feb 23, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
15,243——15,245Feb 22, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
6,026$8.70$52.4K3,090,821Feb 22, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
15,243——3,096,847Feb 22, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
10,000$9.25$92.5K3,081,604Feb 20, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
75,000$7.88$590.9K3,091,604Jan 20, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
76,967$6.54$503.4K3,166,604Jan 20, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
15,243——3,249,024Feb 22, 2025Feb 25, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
15,243——30,488Feb 22, 2025Feb 25, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
5,453$3.42$18.6K3,243,571Feb 22, 2025Feb 25, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
110,020$2.00$219.9K3,233,781Jan 22, 2025Jan 24, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
110,020——0Jan 22, 2025Jan 24, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
45,731——45,731Feb 22, 2024Feb 26, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
159,146——159,146Feb 22, 2024Feb 26, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
57,200——0Jan 31, 2024Feb 2, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
22,094$3.36$74.2K3,123,761Jan 31, 2024Feb 2, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
57,200——3,145,855Jan 31, 2024Feb 2, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
57,199——57,200Sep 1, 2023Sep 6, 2023 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
57,199——3,088,655Sep 1, 2023Sep 6, 2023 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
114,399——114,399Aug 25, 2023Aug 28, 2023 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
10,714——10,714Mar 23, 2022Mar 25, 2022 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
88,787$16.18$1.44M3,102,507May 25, 2021May 25, 2021 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
21,223$16.02$340.1K3,191,294May 24, 2021May 25, 2021 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
14,990$16.09$241.2K3,212,517May 21, 2021May 25, 2021 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
56,967——0May 5, 2021May 7, 2021 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
56,967$1.75$99.9K3,227,507May 5, 2021May 7, 2021 ↗View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Jan 4, 2021Jan 6, 2021 ↗View →
CUE
CUE BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
9,600——9,600Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · IBRX
Loading peer insiders…
About this filer
CIK 0001647994
ROLE
Director
PRIMARY
IBRX
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001647994DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback